Catalyst Pharmaceuticals Inc
CPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.84B
Close$
$16.80
46.5% downside
Current Fair Value
46.5% downsideOvervalued by 46.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.84 Billion |
|---|---|
| Enterprise Value | $3.09 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.75 |
| Beta | 0.74 |
| Outstanding Shares | 122,254,171 |
Return
| Return on Equity | 21.85% |
|---|---|
| Return on Assets | 19.29% |
| Return on Invested Capital | 27.65% |
Valuation & Multiples
| P/E Ratio | 17.43 |
|---|---|
| PEG | 141.36 |
| Price to Sales | 7.85 |
| Price to Book Ratio | 3.93 |
| Enterprise Value to Revenue | 5.17 |
| Enterprise Value to EBIT | 11 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.40
Average shareholder expectationRevenue Estimate
$143.86 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.48
Average shareholder expectationRevenue Estimate
$155.79 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.3141▲ 70.13% |
|---|---|
| Total Calls | 117,800▲ 60.05% |
| Total Puts | 154,800▲ 243.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 85.52%▲ 0.69% |
|---|---|
| Total Invested | $2.59B▲ 6.73% |
| Investors Holding | 388▲ 9.00% |
ESG Score
No data
About Catalyst Pharmaceuticals Inc
CEO: Patrick McEnany Relevant Senate Committees
Finance
Controls Medicare and Medicaid reimbursement policy; as these programs are major payers for specialty drugs, this committee directly impacts Catalyst's revenue.
Health, Education, Labor, and Pensions
Directly oversees the FDA and the NIH; this committee's actions on drug approval pathways and healthcare policy are critical to Catalyst's core business.
Special Committee on Aging
This committee frequently investigates drug pricing and access for chronic conditions, creating high 'headline risk' and regulatory pressure for companies like Catalyst.